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Nalbuphine (Nubain):
non-prescribed use, injecting,
and risk behaviors for blood-
borne viruses
BY KAREN McELRATH AND DOMINIC CONNOLLY
Nalbuphine hydrochloride is a synthetic opiate with agonist-antagonist
properties that has been prescribed for pain relief in several countries
in North and Central America, Europe, and elsewhere. Marketed for
several years under the tradename Nubain®, the drug was believed to
have low potential for dependence. Research into nalbuphine misuse is
limited but studies have documented misuse among some bodybuilders,
weightlifters, and users of anabolic steroids. This study examines
patterns of nalbuphine misuse and injecting behaviors that pose risk
for blood-borne viruses among ten respondents residing largely in one
community in Ireland. Contrary to other research findings, most
individuals had no history of weightlifting and no experience with the
use of anabolic steroids. Most ofthe respondents had injected
nalbuphine several times per day, and reported frequent injection of
stimulants. Tampered bottle caps had been observed by respondents
who also reported that needles and syringes were scarce. At least some
ofthe nalbuphine in the region has been found to be "counterfeit."
Implications of the findings are discussed.
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the authors. The authors are grateful to earlier comments from Andrew
McBride, Lee Monaghan, and Harrison G. Pope.
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For approximately 25 years, nalbuphine hydrochloride
(Nubain®), a synthetic opiate with agonist-antagonist
properties, was prescribed for pain relief in several countries
in North and Central America, Europe, and elsewhere. The
drug was distributed in parenteral solutions only, so that
injection was the primary method of administration. In
December 2004, Bristol-Myers Squibb, the manufacturer of
Nubain®, discontinued worldwide production of the drug.
Company staff in a United Kingdom (UK) office later
reported that low profits generated from Nubain®
prescriptions contributed to the decision to discontinue
production—at least in Europe (communication with Bristol-
Myers UK office, October 19, 2005). Bristol-Myers Squibb
still holds the license for Nubain®, however, other
pharmaceutical companies may distribute nalbuphine, if
licensed under different names.
Early reports concluded that there were "no known cases of
street abuse" involving nalbuphine (Peachey 1987:352), and
the drug was believed to produce low levels of dependency
(Jasinski & Mansky 1972; Schmidt et al. 1985).' However,
the number of prescriptions for nalbuphine increased during
the 1990s in some countries, leading some scholars to suggest
that the drug had greater "addictive potential" than previously
assumed (Camacho et al. 2001:469; Wines et al. 1999:161).
Very few studies have focused on nalbuphine misuse, and
research that has addressed the issue has focused primarily on
individuals with a history of body building, weightlifting, or
anabolic steroid
Three studies have documented nalbuphine misuse among
bodybuilders or anabolic steroid users in England or Wales
(McBride et al. 1996; Monaghan et al. 2000; Williams et al.
2000). Combined, the data from the studies were collected
from a total of 17 respondents or clients. Years of use (range
1 to 8 years) was reported by Williams et al. (2000) and peak
daily dosage reached or exceeded 100 mg for some
respondents in all three studies. Intravenous use often
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followed subcutaneous or intramuscular injection, and
frequent daily injections were common. Although the authors
of one study reported that a few respondents had "shared"
injecting equipment (Williams et al. 2000:20), data regarding
injecting behaviors generally were not described in the
studies. Clients initiated nalbuphine injections primarily to
treat pain associated with injury or weightlifting (McBride et
al. 1996; Williams et al. 2000). However, Monaghan et al.
(2000:section 5.8) found that persons who had injected
nalbuphine did not describe the drug as a "useful training
aid," and most interviewees in that study condemned the use
of nalbuphine, likening the drug to heroin and assigning
"junkie" status to users of the drug.
Misuse of nalbuphine also has been reported among anabolic
steroid users in the United States. Wines et al. (1999)
interviewed 11 respondents who were users of anabolic
steroids and nalbuphine. Respondents were recruited from
other research projects that addressed the use of anabolic
steroids, a drug treatment inpatient unit, and a psychiatric
outpatient setting. Respondents' ages ranged from 19 to 42
years, and five of the 11 respondents were female. Similar to
research conducted in the UK described above, daily dosage
of nalbuphine often exceeded 100 mg per day. Eight of the 11
respondents reported that nalbuphine was the first drug that
they had used intravenously. In a separate study of 227 males
in treatment for opiate dependency, 21 reported a history of
anabolic-androgenic steroid use. The majority of this group
reported that they had used opiates to reduce the negative
effects, e.g., insomnia, depression, irritability, of their steroid
use (Arvary & Pope 2000).
Taken together, this body of research suggests that
nalbuphine misuse has been associated largely with
bodybuilders or weightlifters, although misuse of the drug
does not appear to be widespread within these groups. Some
but not all of the individuals who participated in these studies
also had used anabolic steroids.
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In the mid- to late 1990s, anecdotal and media reports as well
as observations by health professionals suggested the
possibility of a pattern of nalbuphine misuse in Derry, a city
located in Northern Ireland.' Prior to this time, drug treatment
professionals in the region had not come across the use of
nalbuphine among clients presenting for treatment. Because
clients presenting for treatment were injecting the drug,
treatment professionals also were concerned about the
transmission of blood-borne viruses through injecting
practices. In Northern Ireland, public health and
epidemiological data on nalbuphine use and misuse are not
collected. A Northern Ireland general population survey of
3,516 persons aged 15-64 found that self-reported lifetime
use of nalbuphine was slightly higher in the Western health
board that includes the city of Derry (.2% overall; .4% among
males and younger persons), compared to the three other
health board areas (overall 0-.l%) (MORI MRC, n.d.). A
total of 591 individuals residing in the Western board
participated in the survey, therefore these figures are small,
i.e., representing fewer than three respondents. Additionally,
surveys may underestimate drug use/misuse. Arrest and
seizure data involving nalbuphine have limited relevance
because nalbuphine is not controlled under the (United
Kingdom) Misuse of Drugs Act (the drug is also non-
scheduled in the United States). Thus, possessing the drug for
personal use is not a criminal offense, although the supply of
nalbuphine without medical authorization does violate the
Misuse of Drugs Act. As of November 2004, police in the
Derry area recalled only one criminal conviction involving
nalbuphine (communication with the Police Service of
Northern Ireland, Drug Liaison Unit, Derry; November 12,
2004).
The purpose of the present study was twofold. First, we
explored patterns of nalbuphine use among a small sample of
respondents residing largely in Derry, Northern Ireland.
Second, we examined risk behaviors for blood-borne viruses,
in relation to nalbuphine injection.
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Methods
Study announcements were distributed through a number of
venues, e.g., two pharmacy-based needle exchange schemes,
local community schemes, drug services, health centers, and
the offices of selected general practitioners in the Derry area.
The first author visited two gyms in the Derry area that were
known to be frequented by bodybuilders. However, staff there
would not permit copies of the study announcement to be
placed on notice boards, claiming that nalbuphine was not
used in the gyms. In addition to distributing study
announcements through various venues, respondents who
completed an interview were asked to refer other potentially
suitable respondents to the study.
The interview guide concentrated primarily on first and last
use of nalbuphine, patterns of drug taking, risk behaviors
associated with injecting and experiences with drug
treatment. Face-to-face interviews were used to collect the
data. Interviews were conducted during 2003-2004 in private
residences, semi-public areas, or other settings that were
convenient to the respondent. Interviews were not taped;
rather the first author took very detailed notes while she
conducted the interviews. This decision was influenced
primarily by the local social and political context in relation
to drug use. The use of drugs (other than alcohol) and
injection in particular are highly stigmatized behaviors in the
communities where potential respondents were thought to be
residing. The various informal social control mechanisms that
are in place (McElrath 2004) deter individuals from revealing
aspects of their identities associated with illicit drug use.
Taped interview data produces voice identification so that at
times tapes are viewed suspiciously.
Ethical approval was obtained from the Queen's University
Medical Ethics Committee. Respondents were assured
confidentiality and anonymity and paid £20 for a completed
interview. The detailed interview notes were reviewed several
326 NALBUPHINE (NUBAIN): INJECTING AND RISK BEHAVIORS
times within 48 hours of each interview, and then typed by
the first author. Themes emerged which were explored further
as the interviews progressed, and coding schemes were
developed.
Findings*
Ten persons were recruited for an interview. Respondents'
ages ranged from 21 to 50 years. Most respondents were male
although many reported knowing females who had used
nalbuphine. A female injector who was interviewed in a
larger study of injecting drug use (McElrath & Jordan 2005)
reported knowing other females who initiated injection
through nalbuphine, although they subsequently preferred to
inject heroin.
At the time of the interview, three respondents were in full-
time employment and four respondents owned their homes.
None were homeless. The majority (N=7) lived with a
partner, and only one respondent reported that the partner also
used nalbuphine regularly. Two respondents reported a
relatively "active" nightlife consisting of frequent visits to
local clubs.
Seven of the ten respondents resided in the Derry area at the
time of the interview. Three others resided in or near
Ballymena, a town located approximately 50 miles from
Derry, and characterized by a disproportionate number of
heroin users. Contrary to previous research into the misuse of
nalbuphine, only two respondents in the present study had a
history of bodybuilding or weightlifting.
Patterns of The age at which nalbuphine was first used ranged from 18 to
nalbuphine 34 years, and none of the respondents had been prescribed
use nalbuphine for pain relief. Four persons were injected first by
a bodybuilder. One respondent, a former bodybuilder, was
injected first by a female who worked in a health profession.
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Nine of ten respondents reported that they had not "planned"
to inject nalbuphine; rather, they were in the presence of
another individual who had injected it before and the drug
was available in this setting. Four respondents reported that
nalbuphine was the first drug that they had injected.
One respondent was 22 years of age when he first injected
nalbuphine. He had never used opiates prior to using
nalbuphine and he recalled that his drug use was confined
largely to alcohol and cannabis:
"I was selling drugs [cannabis] at the time. A friend —well, a so-
called friend said, 'Try some of this [nalbuphine].' I was drunk and
tried it then and that was me, hooked."
I: "How did it make you feel?"
R: "Sick—I was so sick for the first few times, but it was a good
feeling."
The male acquaintance showed him how to inject into a vein.
The respondent was self-injecting by the second injection
episode which occurred approximately two weeks later. A
respondent and former bodybuilder recalled his first injection
of nalbuphine, which occurred in the late 1980s in the
Ballymena area, about five years after he had first injected
anabolic steroids:
"I was with a mate then, from XXX [small village located near Bal-
lymena]. He gave me a 10 ml bottle of Nubain®, said, 'Put that into
your vein.' I used it in a muscle first and used 1 ml at a time. The
second time I used it, I injected into a vein. Used an insulin needle
then. Real addictive stuff."
This respondent recalled a network of approximately 30
bodybuilders who used nalbuphine during the 1980s-1990s
and resided in Derry, Ballymena, and areas located near these
regions.
Four of ten respondents reported current use of nalbuphine
(i.e., injected during the past 30 days), and the majority
(N=8) had injected either nalbuphine or other drug during the
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30-day period prior to the interview. Nine had injected
nalbuphine intravenously and frequent users of nalbuphine
most often injected into a vein located in the arms or legs:
"You might be able to inject into a muscle but I think your arm
would go black."
Two respondents had injected nalbuphine into the groin area,
although only one had injected nalbuphine into the neck.
One respondent injected nalbuphine each day for a period of
four to five years and two others injected the substance for
approximately eight years. A 10 ml bottle of nalbuphine can
be used for at least 10 injections when using a 1 ml syringe.
These three respondents reported peak usage at 10 mis per
day, injecting every few hours, and a fourth had injected
approximately 12 mis per day at peak usage. Seven of ten
respondents recalled lengthy periods of time in which they
had injected nalbuphine daily.
A former bodybuilder reported peak usage of three times per
day with 3 mis used during each injection episode. He first
injected into a muscle,' however, after injecting into a vein
for the first time:
"I never used it again in a muscle. There's not really a buzz when
you inject Nubain® into a muscle. But into a vein — a big differ-
ence. Once you want one you want another. I found myself waking
up in the morning and injecting it. Never was like that before. I got
so I didn't want to go out, would have a hit just to feel good, had
nothing to do with recovering from a workout. I used it for six
months and it started to affect my lifestyle. I even started not going
to the gym. I just had to stop using."
One respondent had used nalbuphine for several years, and
reported a peak usage of approximately 20 mis per week. The
respondent injected .2 to .4 mis during each injection.
Although the weekly dose was comparatively low, he
reported an average of 75 injections per week at peak usage.
A similar pattern of frequent injecting was observed in
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research conducted with bodybuilders (i.e., Williams et al.
2000).
Use of Nine of ten respondents reported that cannabis was the first
nalbuphine "illicit" drug that they had used. Only one person (a female)
and other had used cannabis and nalbuphine only; other respondents
drugs reported a history of occasional or frequent use of 3.4-
Methylenedioxymethaphetamine (MDMA) and amphetamine
that preceded nalbuphine injection.
Six respondents had used heroin. Of this group, four had
injected heroin, and two had smoked heroin on one occasion
only, but had never injected it. Thus, four individuals had
injected both nalbuphine and heroin. Of this group, two
respondents had injected nalbuphine prior to injecting heroin
whereas two others had injected heroin prior to injecting
nalbuphine. Two of the ten respondents had used nalbuphine
on one occasion only when their drug of choice (i.e., heroin)
was not accessible. Both had been injecting heroin for at least
two years prior to using nalbuphine, and neither resided in the
Derry area. One of these respondents reported:
R: "You can get it on the Intemet. I was off the gear [heroin] for 2
or 3 days. They say you have to be off the gear for a few days
before you start taking it [nalbuphine]. Not as strong as gear would
be. [Small village in County Antrim] —seems to be about there. I
didn't like it that much. Rushes, a downer. It just wasn't the feeling
I liked. First rush I got off Nubain® was something like MSTs
[Morphine Sulphate Tablets]."
The respondent reported that he had been given nalbuphine
by a male acquaintance who was a bodybuilder:
I: "Did you inject into a muscle or a vein?"
R: "I think it was a muscle. I think he injected me in the bum."
I: "Can you get a habit from Nubain®?"
R: "I think they must have had a habit, because they were taking
the gear [heroin] and then they went off that, then on the Nubain®.
Must have been habits."





I: "Would it stop the sickness? Stop the rattling [withdrawal], if you
were using the gear?"
R: "Well it sorted me out for a few days.'"
Although six respondents in the present study had used heroin
and four had injected it, most respondents belonged
exclusively to social networks that were not overtly
connected to networks of heroin users.
Five respondents who reported regular use of nalbuphine
tended to also report frequent use of stimulant drugs,
although not necessarily during the same time periods. For
example, one respondent began to inject cocaine after
initiating injecting with nalbuphine. He estimated that his
peak use of cocaine was 3 to 4 grams administered through
10 to 15 injections per day. This pattern continued for a
number of years until a personal crisis prompted him to cease
using cocaine. At the time of the interview he had not used
cocaine in five months and recovery was largely due to self-
help. However, he still was injecting nalbuphine on a daily
basis. Another respondent initiated injection with anabolic
steroids, injected nalbuphine intravenously for a period of
approximately six months and then proceeded to smoke and
inject crack cocaine for seven years. He had smoked heroin
for a period of one year but only to ease the "come down"
associated with crack cocaine. Two other respondents
injected nalbuphine for a period of several months, but
preferred to inject amphetamine. In their U.S.-based study of
weightlifters who injected nalbuphine. Wines et al. (1999)
observed that 5 of 11 respondents had a history of
dependence on cocaine or other stimulant drug.
The interview data revealed that the price of nalbuphine
varied widely over time and context. Some respondents in the
Derry area recalled that a 10 ml bottle of nalbuphine at one
time sold for £25. Several vials are sometimes sold in one
package with the vials wrapped in cellophane. One
respondent reported that the appearance of the packaging
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resembled "stink bombs." Another respondent reported that
he had recently paid £40 for a box of 10 vials of nalbuphine.
Each vial contained 2 ml of nalbuphine, and there were 20 ml
of nalbuphine in the entire box, a cost of £2 per 1 ml of
nalbuphine. Similar to other drugs purchased on the illicit
market, nalbuphine appears to cost less when purchased in
bulk by a regular supplier. One respondent reported that
nalbuphine was available for purchase through on-line
"pharmacies," although none of the respondents reported
obtaining the drug through these sources.
In early 2004, the first author of the present study was
conducting an interview during which the respondent showed
the author a box containing several vials of liquid that the
respondent had purchased a few days before the interview.
The box contained 10 vials and the printed information on the
box and the vials stated that the substance was Nubain®.
Information on the box stated that the product was
manufactured by DuPont, however, DuPont ceased
production of all Pharmaceuticals approximately three years
earlier. Given the drug's reputed shelf-life of three years, it is
possible that the vials observed did contain Nubain® and
were indeed manufactured by DuPont pharmaceuticals. It is
also possible that the observed vials contained counterfeit
Nubain®, or some other substance. In 2002, the police in
Northern Ireland confiscated a "large quantity" of Nubain®,
determined to be counterfeit because the batch number did
not match with data reported by Bristol-Myers Squibb. The
box of vials observed by the first author contained
instructions that appeared to be written in Arabic. Other
respondents had never observed instructions printed in
Arabic, however, respondents reported that the instructions as
well as the box were often destroyed by persons who supplied
them the drug. On a separate occasion, the second author of
this article observed a vial of liquid, allegedly containing
nalbuphine. However, the name Nubain® was spelled
incorrectly. Taken together, these observations suggest the




possibility that counterfeit Nubain® was sold in the Derry
area. Unfortunately, we have no way of knowing whether
counterfeit Nubain® contained nalbuphine at all.
Injecting behaviors that pose risk for infectious disease, e.g.,
HIV and Hepatitis C virus, appear to differ somewhat when
injecting nalbuphine in comparison to heroin. For example,
injecting heroin often involves the loaning or borrowing of
needles/syringes, filters, spoons and water, and these
behaviors have been linked with Hepatitis C among Injecting
Drug Users (IDUs) (Hagan et al. 2001; Thorpe et al. 2002).
Nalbuphine is typically available in liquid form so that filters
and spoons are not needed to prepare the substance for
injection. Thus, needles, syringes, and rinse water represent
the primary injecting "tools" that can serve as conduits for
the transmission of blood-borne viruses among nalbuphine
injectors. Risk may be escalated, however, because regular
use of nalbuphine often involves several injections per day;
injection frequency has been linked with Hepatitis C
seroconversion among IDUs (Hahn et al. 2001; Patrick et al.
2001).
Respondents reported that nalbuphine is a clear liquid that is
available in a bottle (ampules) or vial. The vial is preferred
because respondents have observed tampered caps on the
bottles:
"You can see the wee holes [from other needles] in the cap."
Tampered bottle caps also were believed to produce a white
residue and a loss of "pressure" in the bottle. One respondent
reported that a dealer would use a needle to remove some of
the nalbuphine from a bottle and then substitute with 2 mis of
water. Another recalled:
"I paid £50 one Christmas for one handful of Nubain®. Some deal-
ers would draw a bit into a syringe and sell you the syringe if you
couldn't afford a bottle."
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Bottles tampered with the needles of others could pose risk
for blood-borne viruses, particularly if the needle or syringe
has been used previously.
Additionally:
"There are weak bottles and strong bottles. And there's counterfeit
Nubain®. There are posters put up by the Police Service of North-
ern Ireland (PSNI) [police] and they are about counterfeit Nubain®.
See, real Nubain® comes in a vial. Counterfeit Nubain® comes in a
brown bottle, and you just stick your pin [needle] through it."
Here, the type of container that held the Nubain® was the
criterion used to determine whether it was counterfeit.
According to this respondent, Nubain® was distributed
through vials, whereas the counterfeit substances were supplied
in bottles. As described earlier, police in Northern Ireland
confiscated several vials of counterfeit Nubain® in 2002.
Respondents recalled the scarcity of needles/syringes prior to
the implementation of pharmacy-based needle exchanges in
2001. A respondent recalled that needles/syringes were sold
for £1 each from certain dealers who were selling nalbuphine.
Two other respondents provided similar accounts. This source
of distribution also occurred after the provision of the two
pharmacy-based needle exchanges in the area. Local drug
suppliers were known to obtain needles (either directly or
indirectly) through the exchange schemes and either sell or
distribute them freely to buyers of nalbuphine. In particular,
the free distribution via secondary exchange assisted
respondents who had never visited an exchange. For these
respondents, visits to the exchange represented a "wild
embarrassing situation":
I: "So why won't you use the needle exchange?"
R: "I can't admit to using drugs, without getting any help. It's bad
enough letting them know I used to use Nubain®. To get your nee-
dles from the exchange, you'd have to admit to using. I never used
it [exchange] once."
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The scarcity of needles led respondents to use one needle
several times over a period of days:
"You'd hang onto them because they were so hard to get."
A former bodybuilder injected anabolic steroids before
injecting nalbuphine. He recalled learning how to inject from
a friend who worked in nursing:
R: "She injected me and a mate. She used two needles."
I: "Do you mean two separate needles? One for you and one for
your mate?"
R: "Yeah, but she used two separate needles for each of us. Once
you draw the steroid up, you replace the needle. See, that first nee-
dle you use to break the cap. She said it damages a bit, and if you
used it again there would be a risk for infection. So she taught us to
replace the needle and use a new one for injecting the steroid."
Six respondents had engaged with drug treatment services,
and five were in treatment at the time of the interview. One of
these individuals, however, had used nalbuphine on one
occasion only and had been prescribed high-dose buprenorphine
(Subutex®) for heroin dependence. Two others were prescribed
high-dose buprenorphine and reported that they had since
Treatment abstained from using nalbuphine and heroin. Both were
injecting amphetamine but reported that their frequency of
injecting had declined from several times to once a day since
commencing the program of substitute prescribing. One
respondent who had never engaged with drug treatment
services had been prescribed diazepam by his doctor and he
attributed his abstinence to this medication and the support of
a family member. One other respondent had never
participated in drug treatment but was actively involved with
a local self-help group.
Discussion
Empirical research into nalbuphine misuse is limited and
studies that have focused on the issue have drawn primarily
from samples of bodybuilders or weightlifters. In the present
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study, eight of ten respondents had never participated in
bodybuilding or weightlifting, nor had they used anabolic
steroids. A few case studies and reports have highlighted
nalbuphine misuse among individuals with no reported
history of bodybuilding or weightlifting (e.g., Camacho et al.
2001, United States Food and Drug Administration, n.d.).
However, to our knowledge this study is the first to describe
patterns of nalbuphine misuse among individuals —of whom
most had no prior experience with bodybuilding or
weightlifting.
Our data cannot inform us about the extent of nalbuphine
misuse in the Derry area. Research from other countries, e.g.,
the United States, has identified upward trends of the misuse
of opiates that are generally available from prescription only
(McCabe et al. 2005; Volkow 2005). In particular, U.S. data
have shown increases in the misuse of other opioid analgesics
that are intended to relieve pain (Drug Abuse Warning
Network 2004; Gilson et al. 2004). It is unclear whether
similar patterns will follow in Ireland. We also are unable to
explain why nalbuphine misuse surfaced in Derry but does
not appear to have surfaced in other parts of Northern Ireland,
including its largest city, Belfast (e.g., MORI MRC, n.d.).
Considerably more research is needed into drug preferences
and how local contexts might shape these preferences.
From the limited number of interviews with nalbuphine users,
there appeared to be no clear pattern regarding the sequence of
the drugs that respondents had injected. For example, using
nalbuphine did not necessarily contribute to the likelihood of
injecting heroin. The data do suggest, however, that several of
the nalbuphine users interviewed for this study became
frequent users of cocaine or other stimulants. This pattern of
polydrug use has also been observed in studies of nalbuphine
use in the Boston area (Wines et al. 1999) and in Brighton
(England) (Williams et al. 2000). In the latter study, the
authors suggested that cocaine use was associated primarily
with the occupational lifestyles of many of the clients, who
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tended to be employed in nightclubs where accessibility and
opportunity to use cocaine may be enhanced. In the present
study, some of the stimulant users were loosely connected
with social networks of other drug users which may have
provided opportunity to access other drug markets. However,
one respondent with a lengthy history of cocaine use had few
connections with users of other drugs and attempted to
distance himself from these networks.
The data suggest that the use of nalbuphine can contribute to
risk behaviors for blood-borne viruses. First, users reported
injecting the drug several times per day. The frequency of
injection can increase exposure to blood-borne viruses
particularly among persons who inject with others. Second,
respondents reported that nalbuphine was available in both vials
and bottles, and some had observed bottle caps in which a
needle had previously been inserted. These observations suggest
that other users or suppliers had inserted needles into the cap,
probably to draw nalbuphine from the bottle for their own
personal use or to increase profit. The risks associated with
"sharing" common ampules containing other drugs have been
highlighted in studies conducted in India (Sarkar et al. 2003) and
in New York City (Lankenau & Clatts 2002). Third, respondents
reported difficulties in accessing new needles/syringes,
particularly before the two pharmacy-based exchanges were
implemented. Moreover, some respondents sought to conceal
their drug use and in doing so, avoided the exchanges entirely.
As a result, respondents sought injecting equipment through
secondary exchange or through drug suppliers.
We have no way of knowing the extent to which people have
sourced counterfeit Nubain®, although we know that counterfeit
supplies have been identified in Northern Ireland. Similarly,
we do not know the extent to which prescribed Nubain® has
been diverted to illicit drug markets in Northern Ireland. It is
possible and perhaps likely that some diversion has occurred.
Given the pharmaceutical company's decision to cease
production of Nubain® we are concerned about the potential
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impact on individuals who are dependent on the drug and
have sourced nalbuphine largely through diverted markets.
Will they now access counterfeit Nubain®, will they abstain,
or will they substitute with other opiate drugs? They have
administered the drug via intravenous injection and may
continue administering other drugs in this way. Clearly, we
need to monitor the situation through additional research and
discussions with clients entering treatment.
One limitation of this study concerns its small sample size
(N=10); larger samples might yield more diverse data with
regard to patterns of use and injecting behaviors. Clearly
more research with larger samples of persons who inject
nalbuphine is needed. Second, these cross-sectional data
impede our ability to ascertain how changes in the marketing
of Nubain® might have affected persons who use the drug.
N o t e s 1. Note, however, that Schmidt et al. were employed by DuPont Phar-
maceuticals, which marketed nalbuphine under the trade name
Nubain until 2001.
2. One report contained a brief mention of nalbuphine misuse among
methamphetamine users in Korea. The authors indicated that some
individuals consumed nalbuphine when methamphetamine became
less available in the region (Yoo et al. 1995). Regarding the misuse
of nalbuphine, no other details were provided by the authors.
3. In 2001. the population of the Derry City Council area was estimated
to be approximately 105,000.
4. Respondent ID numbers that normally accompany quoted material
from interviewees, are omitted from this article in order to maintain
anonymity. Most of the respondents reside in a small city and some
health professionals are aware of some treatment clients' participa-
tion in the study. We believe that if IDs or related information were
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